KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Other Accumulated Expenses (2016 - 2020)

Historic Other Accumulated Expenses for Regeneron Pharmaceuticals (REGN) over the last 10 years, with Q4 2020 value amounting to $122.4 million.

  • Regeneron Pharmaceuticals' Other Accumulated Expenses rose 4400.0% to $122.4 million in Q4 2020 from the same period last year, while for Dec 2020 it was $122.4 million, marking a year-over-year increase of 4400.0%. This contributed to the annual value of $122.4 million for FY2020, which is 4400.0% up from last year.
  • Per Regeneron Pharmaceuticals' latest filing, its Other Accumulated Expenses stood at $122.4 million for Q4 2020, which was up 4400.0% from $96.9 million recorded in Q3 2020.
  • In the past 5 years, Regeneron Pharmaceuticals' Other Accumulated Expenses registered a high of $122.4 million during Q4 2020, and its lowest value of $267000.0 during Q4 2017.
  • In the last 4 years, Regeneron Pharmaceuticals' Other Accumulated Expenses had a median value of $3.7 million in 2016 and averaged $39.8 million.
  • In the last 5 years, Regeneron Pharmaceuticals' Other Accumulated Expenses soared by 51821.51% in 2016 and then crashed by 9351.5% in 2017.
  • Regeneron Pharmaceuticals' Other Accumulated Expenses (Quarter) stood at $1.2 million in 2016, then plummeted by 77.33% to $267000.0 in 2017, then soared by 31735.21% to $85.0 million in 2019, then soared by 44.0% to $122.4 million in 2020.
  • Its Other Accumulated Expenses was $122.4 million in Q4 2020, compared to $96.9 million in Q3 2020 and $103.8 million in Q2 2020.